A Single-center, Prospective, Self-controlled, Observational Real-world Study of the Efficacy and Safety of Anti-IL-17A/F Monoclonal Antibody Combined With Non-ablative Dot Laser for the Treatment of Mild to Moderate Hidradenitis Suppurativa
Latest Information Update: 05 May 2026
At a glance
- Drugs Bimekizumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
Most Recent Events
- 05 May 2026 New trial record